Tempest Therapeutics Inc. (TPST)
0.82
0.01 (1.31%)
At close: Mar 03, 2025, 11:54 AM
No 1D chart data available
| Bid | 0.82 |
| Market Cap | 35.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.06M |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 148,683 |
| Avg. Volume (20D) | 1,263,234 |
| Open | 0.82 |
| Previous Close | 0.81 |
| Day's Range | 0.81 - 0.82 |
| 52-Week Range | 0.70 - 6.00 |
| Beta | -2.66 |
About TPST
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 12, 2012
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TPST
Website https://www.tempesttx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for TPST stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 1481.51% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-10.5%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
6 months ago
+30.25%
Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.
